Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biotest GmbH KGaA (LTS:0N6Z) Property, Plant and Equipment Explanation
A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.
Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.
Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.
Biotest GmbH KGaA Property, Plant and Equipment Related Terms
Biotest GmbH KGaA Property, Plant and Equipment Historical Data
* Premium members only.
The historical data trend for Biotest GmbH KGaA's Property, Plant and Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotest GmbH KGaA Property, Plant and Equipment Chart
Biotest GmbH KGaA Property, Plant and Equipment Calculation
Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.
Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.
Some of the most common parts of property, plant, and equipment are:
Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:
Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars
There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.
The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.
For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.
All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.
The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.
What does a Property, Plant and Equipment of £0.00 Mil mean?
Biotest GmbH KGaA (LTS:0N6Z) has a Property, Plant and Equipment of £0.00 Mil as of . 20. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Biotest GmbH KGaA and its competitors.
Is Biotest GmbH KGaA's Property, Plant and Equipment too high?
Biotest GmbH KGaA's current Property, Plant and Equipment is £0.00 Mil.
How does Biotest GmbH KGaA's Property, Plant and Equipment compare to ?
Biotest GmbH KGaA's Property, Plant and Equipment of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Property, Plant and Equipment for a Biotechnology company?
A good Property, Plant and Equipment depends on the Biotechnology industry context. However, Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Property, Plant and Equipment mean?
A high Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Biotest GmbH KGaA and its competitors. Biotest GmbH KGaA's current Property, Plant and Equipment is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current Property, Plant and Equipment of £0.00 Mil. The current Property, Plant and Equipment is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Property, Plant and Equipment calculated?
Property, Plant and Equipment is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current Property, Plant and Equipment is £0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0N6Z has been successfully added to your 
